MYD88 and hepatocellular carcinoma: APs may modulate immunity by activating the toll-like receptor 4 (TLR4)–mediated myeloid differentiation primary response 88 (MyD88)–dependent signaling pathway [22] and induce apoptosis in human hepatocellular carcinoma cells by decreasing the expression of Notch1 [23].